Product Information
SEVELAMER HCL 800 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.6952 per EA under NDC 70710205808. Its NADAC has been published 69 times since Jun 11, 2025.
FDA first approved this application on Feb 3, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
800 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710205808
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SEVELAMER HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA218966FDA Approved
2/3/2025
TE Code
AB
On Market Since
3/1/2025
Pharmacological Classes
Price Statistics
The NADAC for SEVELAMER HCL 800 MG TABLET has been published 69 times since Jun 11, 2025, and over the history we have for it it has declined 39.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6952 per EA |
|---|---|
| All-time high | $1.3679 (Sep 10, 2025) |
| All-time low | $0.6952 (Sep 23, 2026) |
| 52-week high | $1.3660 |
| 52-week low | $0.6952 |
| Median price | $1.0471 |
| Average price | $1.0205 |
| Largest weekly change | -11.4% (Nov 19, 2025) |
| Weeks tracked | 69 |
| Tracking since | Jun 11, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sevelamer Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphate Binder class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SEVELAMER HCL 800 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SEVELAMER HCL 800 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.6952 per EA (NDC 70710205808), effective Sep 30, 2026.
How has the price of SEVELAMER HCL 800 MG TABLET changed over time?
Over the history we have for it, the NADAC for SEVELAMER HCL 800 MG TABLET has declined 39.4%. It has been tracked across 69 weekly CMS publications since Jun 11, 2025.
What are the highest and lowest recorded NADAC prices for SEVELAMER HCL 800 MG TABLET?
Since Jun 11, 2025, the NADAC for SEVELAMER HCL 800 MG TABLET has ranged from a low of $0.6952 (Sep 23, 2026) to a high of $1.3679 (Sep 10, 2025), with a median of $1.0471 per EA.
Are there cheaper alternatives to SEVELAMER HCL 800 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as SEVELAMER HCL 800 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures SEVELAMER HCL 800 MG TABLET?
SEVELAMER HCL 800 MG TABLET (NDC 70710205808) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.